Did you know?

Track Verrica Pharmaceuticals Inc (VRCA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe stock options have an exercise price equal to $7.65 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on October 12, 2023.VSTM Competitors. $ Market cap P/E ratio $ Price 1d change 52-week range. View Verastem, Inc. VSTM stock quote prices, financial information, real-time forecasts, and company news from CNN.Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Track Terns Pharmaceuticals Inc (TERN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell ...Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients.The forward-looking statements contained in this press release reflect Verastem Oncology's views as of the date hereof, and Verastem Oncology does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.Mr Paterson joined Verastem Oncology in 2011 and was its President and Chief Operating Officer prior to becoming President and Chief Executive Officer in 2023. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief ...BOSTON--(BUSINESS WIRE)--May 31, 2023-- Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock.Verastem's stockholders approved an amendment to Verastem's Restated Certificate of Incorporation (as amended, the ...Verastem Oncology | 13,729 followers on LinkedIn. Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and ...The latest price target for Verastem ( NASDAQ: VSTM) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst firm set a price target for 17.50 expecting VSTM to rise to within 12 ...May 9, 2024 · This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at [email protected]. Press Releases. Media Kit.This press release includes forward-looking statements about Verastem Oncology’s strategy, future plans and prospects, including statements related to cash runway, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including topline data reports, and potential for additional …Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote …5 days ago · www.verastem.com. Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase ...

See the latest Verastem Inc stock price (VSTM:XNAS), related news, valuation, dividends and more to help you make your investing decisions.For many patients with difficult-to-treat cancers, the options have been few. Verastem Oncology aims to change that by pursuing RAS pathway-targeted treatment combinations with avutometinib (VS-6766). Find out more about our clinical trials here. FIND A TRIAL. Verastem-Sponsored Trials Investigator-Sponsored Trials.Unlike a quitclaim deed, a warranty deed transfers the ownership of a property from one person to another while guaranteeing that the title to the property is lien-free. In Texas, ...Mr Paterson joined Verastem Oncology in 2011 and was its President and Chief Operating Officer prior to becoming President and Chief Executive Officer in 2023. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief ...

Investors. At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address ...AMERICAN FUNDS MULTI-SECTOR INCOME FUND CLASS 529-F-2- Performance charts including intraday, historical charts and prices and keydata. Indices Commodities Currencies StocksTrack Arm Holdings Plc. (ARM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Latest FSRN News. No FSRN news at the moment. Track Fiske. Possible cause: Verastem Contacts. Investors: Ajay Munshi Vice President, Corporate Developme.